These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37626778)

  • 1. Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population.
    Jan A; Saeed M; Mothana RA; Muhammad T; Rahman N; Alanzi AR; Akbar R
    Biomedicines; 2023 Aug; 11(8):. PubMed ID: 37626778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Polymorphisms of Cytochrome p450 (2C9) Enzyme in Patients with Type 2 Diabetes Mellitus in Turkmen and Fars Ethnic Groups.
    Rabiee M; Marjani A; Khajeniazi S; Mojerloo M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):653-661. PubMed ID: 30129421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
    Holstein A; Plaschke A; Ptak M; Egberts EH; El-Din J; Brockmöller J; Kirchheiner J
    Br J Clin Pharmacol; 2005 Jul; 60(1):103-6. PubMed ID: 15963101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in the frequencies of polymorphisms in the CYP2C9 gene in six major ethnicities of Pakistan.
    Ahmed S; Altaf N; Ejaz M; Altaf A; Amin A; Janjua K; Khan AU; Imran I; Khan S
    Sci Rep; 2020 Nov; 10(1):19370. PubMed ID: 33168919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
    Gökalp O; Gunes A; Cam H; Cure E; Aydın O; Tamer MN; Scordo MG; Dahl ML
    Eur J Clin Pharmacol; 2011 Dec; 67(12):1223-9. PubMed ID: 21691805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between Aldosterone Synthase (
    Shah WA; Jan A; Khan MA; Saeed M; Rahman N; Zakiullah ; Afridi MS; Khuda F; Akbar R
    Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of HLA-B Gene Polymorphisms with Type 2 Diabetes in Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan.
    Jan A; Saeed M; Afridi MH; Khuda F; Shabbir M; Khan H; Ali S; Hassan M; Samiullah ; Akbar R; Zakiullah
    J Diabetes Res; 2021; 2021():6669731. PubMed ID: 34258292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
    Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of nasopharyngeal cancer risk with genetic polymorphisms of drug-metabolizing enzyme genes GSTM1, GSTT1 and CYP1A1 (rs4646903 variant), in tobacco addicted patients of Pashtun ethnicity of Khyber Pakhtunkhwa Province of Pakistan.
    Zakiullah -; Saeed M; Javed N; Khuda F; Ovais M
    Pak J Pharm Sci; 2019 Sep; 32(5):2107-2116. PubMed ID: 31813877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.
    Muhammad SD; Khan H; Hussain M; Zeb TF; Kumar D; Rahi R; Asif M; Balooch AA
    Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1771-1777. PubMed ID: 33612460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
    Klen J; Dolžan V; Janež A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):421-8. PubMed ID: 24442125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
    Dujic T; Zhou K; Donnelly LA; Leese G; Palmer CNA; Pearson ER
    Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects.
    Hatta FH; Aklillu E
    OMICS; 2015 Dec; 19(12):777-81. PubMed ID: 26669712
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.